Bienaime Jean Jacques's Form 4 filing
Biomarin Pharmaceutical Inc (BMRN) · filed Feb 29, 2024
- Accession no.
- 0001048477-24-000018
- Filed
- Feb 29, 2024
- Trade date
- Feb 27, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 4 non-derivative transactions. Open-market sales total $90.3K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Bienaime Jean JacquesCIK 0001221590 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 27, 2024 | Common Stock | AGrant or awardAcquired | +82,700 | $0.00 | $0 | 502,302 | Direct | |
| Feb 27, 2024 | Common Stock | AGrant or awardAcquired | +35,975 | $0.00 | $0 | 538,277 | Direct | |
| Feb 27, 2024 | Common Stock | AGrant or awardAcquired | +24,926 | $0.00 | $0 | 563,203 | Direct | |
| Feb 27, 2024 | Common Stock | SSaleDisposed | −1,000 | $90.35 | −$90,350 | 562,203 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.